Nippon India Pharma Bonus Bonus Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

Nippon India Pharma Bonus Bonus Growth Direct Plan

NAV
₹586.1846
+0.30%
(17 Jul)
AUM
8,569 Cr
TER
0.89%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+14.1%
-5.6%
-5.6%
-6.7%
-6.7%
3Y
+25.7%
+39.1%
+39.1%
+39.6%
+39.6%
5Y
+22.7%
+32.8%
+32.8%
+31.3%
+31.3%
ALL
+18.5%
+12.3%
+12.3%
+17.1%
+17.1%
VOL
15.6%
20.3%
20.3%
20.3%
20.3%
TER
0.9%
0.8%
0.8%
0.9%
0.9%
AUM
₹8,569 Cr
₹5,427 Cr
₹5,427 Cr
₹1,439 Cr
₹1,439 Cr
INFO
1.18
0.60
0.60
0.84
0.84
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Nippon India Pharma Bonus Bonus (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Jun
Top holdings
Sun Pharmaceuticals Industries Ltd
12.2%
Divi's Laboratories Ltd
8.5%
Lupin Ltd
6.1%
Cipla Ltd
5.6%
Apollo Hospitals Enterprise Ltd
5.5%
Dr Reddy's Laboratories Ltd
5.2%
Medplus Health Services Ltd
3.8%
GlaxoSmithKline Pharmaceuticals Ltd
3.6%
Narayana Hrudayalaya Ltd
3.6%
Vijaya Diagnostic Centre Ltd
3.3%
Top industry exposure
Healthcare
99.5%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
13%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Fund manager(s)
Sailesh Raj Bhan
Kinjal Desai

FAQs